Tofacitinib citrate also known as CP-690550 is an JAK kinase inhibitor. An IC50 estimated at 0.2 μM for PV patient progenitor cells. Find all the information about Tofacitinib citrate (CP-690550) for cell signaling research.
Published News » Science
SGI-1776 free base is a selective Pim family kinase inhibitor with IC50 of 7 ± 1.8, 363 ± 27.6 and 69 ± 9.2 nM for Pim-1, Pim-2, and Pim-3, respectively. Find all the information about SGI-1776 free base for cell signaling research.
BMS-599626 (AC480) is a highly selective pan-HERKinase inhibitor with IC50 of 20 and 30 nM for the inhibition of HER1and HER2, respectively. Find all the information about BMS-599626 (AC480) for cell signaling research.
FDA Accepted Drug Library | API Library | 96-Properly
Posted by rodamewood43 (#15) 5 days ago (http://www.selleckbio.com)
API Library is available at Selleck Chemicals. Other Libraries such as Inhibitor, Kinase inhibitor, Natural Product, Chemotherapeutic Agent, Peptide libraries. The library is ideal database for high-throughput screening (HTS) and cell based high-content screening (HCS).
Find all the information about CI-1033 (Canertinib) for cell signaling research.
PRICE BMS 794833 | c-Met Inhibitor | from provider selleckbio.com
Posted by rovan1 5 days ago (http://www.selleckbio.com)
BMS-794833 is a potent ATPcompetitive Met/VEGFR-2 kinase inhibitor and it also inhibits Ron (Met family),Axl and Flt-3 with IC50 values
MK-0752 is a potent gamma secretase (γ-secretase) inhibitor in clinical development with an IC50 of 5 nM for Aβ40 in human SH-SY5Y cells. Find all the information about MK-0752 for cell signaling research.
BMS-806 (ORDER BMS 378806) from provider selleckbio.com
Posted by rovan1 5 days ago (http://www.selleckbio.com)
BMS-806 (BMS 378806) is a small molecule gp120/CD4 inhibitor with an IC50 of median 5 nM. Find all the information about BMS-806 (BMS 378806) for cell signaling research.
Submit story
Sort News
Pligg is an open source content management system that lets you easily create your own social network.



